WO2001013967A1 - Formulations solides contenant de la fibronectine, destinees a la guerison de plaies - Google Patents

Formulations solides contenant de la fibronectine, destinees a la guerison de plaies Download PDF

Info

Publication number
WO2001013967A1
WO2001013967A1 PCT/CA2000/000953 CA0000953W WO0113967A1 WO 2001013967 A1 WO2001013967 A1 WO 2001013967A1 CA 0000953 W CA0000953 W CA 0000953W WO 0113967 A1 WO0113967 A1 WO 0113967A1
Authority
WO
WIPO (PCT)
Prior art keywords
fibronectin
dressing
wound
solid
delivery system
Prior art date
Application number
PCT/CA2000/000953
Other languages
English (en)
Inventor
Andre Beaulieu
Robert Paquin
Benoit Lariviere
Original Assignee
Andre Beaulieu
Robert Paquin
Benoit Lariviere
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andre Beaulieu, Robert Paquin, Benoit Lariviere filed Critical Andre Beaulieu
Priority to AU66763/00A priority Critical patent/AU781865B2/en
Priority to EP00954211A priority patent/EP1210130A1/fr
Priority to JP2001518100A priority patent/JP2003507440A/ja
Priority to CA002380730A priority patent/CA2380730A1/fr
Priority to GB0203693A priority patent/GB2368523B/en
Priority to MXPA02001576A priority patent/MXPA02001576A/es
Priority to US10/049,992 priority patent/US7112320B1/en
Publication of WO2001013967A1 publication Critical patent/WO2001013967A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0023—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • the present invention relates to solid wound dressings which release effective amounts of fibronectin, in particular fibronectin- calcium alginate dressings.
  • Fibronectin is a ubiquitous extracellular glycoprotein containing around 5% carbohydrate. It exists in a soluble form in body fluids and in an insoluble form in the extracellular matrix. Fibronectin plays a major role in many important physiological processes, such as embryogenesis, hemostasis, thrombosis and wound healing (Potts, J.R. and Campbell, I.D. Current Opinion in Cell Biology 6:648-55, 1994).
  • the characteristic form of plasma fibronectin is a disulfide- bonded dimer of 440,000 daltons, each subunit having a molecular weight of about 220,000 daltons.
  • Plasma fibronectin is also known by various other names, including cold-insoluble globulin, antigelatin factor, cell attachment protein, cell spreading factor, and opsonic alpha 2 -surface binding glycoprotein. These names reflect biological activities of fibronectin such as cell recruitment, opsonization of particulate debris, and promotion of wound contraction. Reviews on structure and activities of fibronectin have been published elsewhere (Hynes, R.O. Fibronectins, Rich, A., ed. New York, Springer- Verlag 1990).
  • Wound healing is usually divided into three phases: the inflammatory phase, the proliferative phase, and the remodeling phase.
  • Fibronectin has been reported to be involved in each stage of the wound healing process, particularly by creating a scaffold to which the invading cells can adhere. Initially, there is a release of many mediators to the wound site such as fibronectin and fibrinogen. Fibronectin promotes inflammatory cell migration into the wound and debris phagocytosis by monocytes. Thereafter, angiogenesis and reepithelialization take place. At this stage, fibronectin exerts chemotactic activity on endothelial cells, and promotes epithelial cell and fibroblast migration onto the basal membrane.
  • Fibronectin also appears to be an essential component of the remodeling phase where it plays a major role in the organization of collagen fibrils.
  • the fibrillar collagen ultimately forms fibrous bundles that greatly enhance the tissue tensile strength, leading to wound closure.
  • fibronectin is extracted and purified using a method developed by Horowitz and Chang (Horowitz, B. and Chang, M.D.Y. "Preparation of fibronectin for therapeutic administration in Fibronectin, D.F. Mosher ed., Academic Press, San Diego 441-455 (1989)).
  • Topically applied plasma fibronectin has been reported as being useful for increasing the rate of wound healing such as in corneal wounds (Nishida, T.
  • a topical formulation which maximizes the contact time of fibronectin to the wound and controls the release of fibronectin into the wound, is a hydrogel formulation.
  • hydrogel In drug delivery, the term hydrogel is typically reserved for polymeric materials that can absorb a significant amount of water (> 20% of its dry weight) while maintaining a distinct three-dimensional structure (Gehrke, S.H. and
  • hydrogels mimic living tissue more closely than any other non- natural material. Their immediate resemblance to tissue is in their soft, flexible nature and high water content. This helps minimize mechanical irritation and damage to body tissues.
  • Other advantages of hydrogel formulations include: ability to keep the wound moist which results from their high water content, ability to absorb excess water (exudate) in the wound, ease of application to and removal (by washing) from the wound. They also provide a cool feeling when topically applied, a property that can increase patient comfort. Hydrogels have four major properties: swelling degree, biocompatibility, permeability and swelling kinetics.
  • Example of such compounds include vinyl polymers (e.g. polyacrylic acid), cellulose and cellulose derivatives.
  • Polyacrylic acid polymer also referred to as carbomer, e.g. Carbopol® carbomer (BF Goodrich)
  • carbomer e.g. Carbopol® carbomer (BF Goodrich)
  • cellulose and cellulose derivatives because it was shown to be superior to other pharmaceutically acceptable formulations in the delivery of fibronectin to skin wounds.
  • Hydrogel formulations comprising a water soluble, pharmaceutically acceptable polymer which can include increasing concentrations of fibronectin are described in U.S. Patent 5,641,483, entitled “Wound Healing Formulations containing Human Plasma Fibronectin", which is incorporated by reference herein in its entirety.
  • Methods for preparing non-buffered aqueous concentrated solutions of fibronectin and hydrogels containing up to 1% of fibronectin are described in U.S. Patent No. 5,821,220, entitled “Method of Producing Concentrated Non-Buffered Solutions of Fibronectin” and International Application No. PCT/CA97/00966, International
  • Alginates are naturally occurring substances extracted from marine brown algae and used in the pharmaceutical, cosmetic, textile and food industry. Alginates are polyanionic polysaccharides composed of linear binary copolymers of D-mannuronic acid and L- guluronic acid. The most common uses are based on the polyelectrolytic nature of the alginates, which provides the basis of their gelling properties and their ability to swell. The commercially available sodium alginates are water soluble. When such alginates are added to a solution containing polyvalent ions, for example bivalent alkaline earth metal ions such as Ca ++ , alginate gels having a semi- solid form are produced. This is a result of a ionic crosslinking of several alginate chains.
  • polyvalent ions for example bivalent alkaline earth metal ions such as Ca ++
  • Calcium alginates have long been known for their ability to form fibres or nonwoven materials. These have been used primarily as swabs or dressings for medical, surgical or other purposes, such as described in European Patent Specification, EP 0721355 Bl, entitled "Alginate Wound Dressings, which is incorporated herein by reference in its entirety. Supplied in the form of nonwoven wound dressings for the treatment of exudating wounds, the calcium alginate dressing is said to encourage the formation of controlled ion-active gel over the wound site which reacts with the sodium ions in the exudate.
  • exudative wounds include pressure ulcers, venous stasis ulcers, diabetic ulcers, arterial ulcers, second degree burns and skin graft donor sites.
  • the present invention provides techniques for the creation of solid wound dressings capable of delivering an effective wound healing amount of fibronectin to a wound site.
  • solid dressings used to deliver the fibronectin are based on calcium alginate, carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC), carbomer and carrageenan.
  • Formulation of topical dosage forms intended for the incorporation of fibronectin should respect several quality criteria. All components of the preparation including solvents and gelling agents should be nontoxic for the wound and compatible with the drug. The final product should promote optimal release of the drug to its site of action, be of adequate consistency to enhance contact time of the drug with the wound and be sterile.
  • solid dressings of the present invention offer specific advantages in terms of dose reproducibility, ease of storage, transport and application. In addition, preservatives are not needed.
  • solid dressings provide a slow release of fibronectin to the delivery site. This should allow for the application of the solid wound dressings on a convenient once a day basis. Due to once a day application schedule and their solid form, the trauma done to the wound by the removal of depleted doses should be minimized.
  • the preferred formulations of this invention can be used with other wound healing promoters having a composition similar to fibronectin, such as proteins of similar size (thrombospondin, laminin, vitronectin, fibrinogen) or smaller size (such as peptides including growth factors).
  • proteins of similar size thrombospondin, laminin, vitronectin, fibrinogen
  • smaller size such as peptides including growth factors
  • the preferred formulations can be evaluated using an in vitro diffusion cell system consisting of a rigid receptor containing a deepithelialized skin sample, the deepithelialized side facing upwards into a donor compartment and the dermal side facing downwards into a receptor compartment as described in detail in U. S. Patent No. 5,877, 149, entitled “Deepithelialized Skin Diffusion Cell System,” which is incorporated herein by reference.
  • the receptor compartment is connected to a circulating buffer circuit, with the buffer temperature maintained at 37°C, while the skin surface is about 32°C.
  • Figure 1 shows absorption of fibronectin in deepithelialized human skin using different solid wound dressings over a 24 hour period.
  • the number in ( ) refers to the quantity of absorbed fibronectin ( ⁇ g) per mm ⁇ of deepithelialized human skin over a 24 hour period.
  • the number in [ ] refers to the quantity of absorbed saline solution (0.9% NaCl) by weight of dressing. Bars represent standard deviations of the mean.
  • Figure 2 depicts new granulation tissue formation, measured as maximum height ( ⁇ m) in response to treatment with a fibronectin- calcium alginate dressing after 7 days of treatment. 6-mm diameter dressings were applied at the time of surgery. Alginate dressing (Kaltostat), collagen-alginate dressing (Fibracol) and fibronectin- calcium alginate dressings were placed on the ulcers and wetted with 40 ⁇ L of saline solution. Control treatment (identified as f" saline”) were ulcers treated with 40 ⁇ L of saline alone. Occlusive dressings (Tegaderm) were used to prevent wound desiccation.
  • Figure 3 illustrates the new granulation volume formed in response to treatment with fibronectin- calcium alginate dressing after time of surgery.
  • Alginate Keltostat
  • collagen-alginate Fibracol
  • fibronectin-calcium alginate dressings were placed on the ulcers and wetted with 40 ⁇ L of saline solution.
  • Control treatment (identified as t"saline") were ulcers treated with 40 ⁇ L of saline alone.
  • Occlusive dressings (Tegaderm) were used to prevent wound desiccation.
  • Figure 4 shows new granulation tissue formation, measured as maximum height ( ⁇ m) in response to 1.0 % fibronectin carbomer hydrogel after 7 days of treatment.
  • the fibronectin was applied as a 0.281% carbomer hydrogel (40 ⁇ L containing 400 ⁇ g of fibronectin) at the time of the surgery and daily during 7 days.
  • the volume of the topical formulations applied to control wounds (saline and 0.281% carbomer hydrogel) was also 40 ⁇ L.
  • Figure 5 illustrates the new granulation volume in response to
  • fibronectin carbomer hydrogel 1.0% fibronectin carbomer hydrogel after 7 days of treatment.
  • the fibronectin was applied as a 0.281% carbomer hydrogel (40 ⁇ L containing 400 ⁇ g of fibronectin) at the time of the surgery and daily during 7 days.
  • the volume of the topical formulation applied to the control wounds was also 40 ⁇ L.
  • Antiseptic tulle gras dressing (Bactigras) and non-adherent absorbent dressing (Melolite) were used to prevent wound desiccation.
  • Figure 6 illustrates the amount of fibronectin absorbed from fibronectin- calcium alginate disks prepared according to Example 1 for various tested amounts of fibronectin. Absorption was measured using the human deepithelialized skin diffusion cell system after 24 hours.
  • Alginate salts as well as the dressing systems described in subsequent examples, can be converted into fibers by a process of freeze-drying. This procedure produces a sponge-like structures with hydrophilic properties. In the presence of fluids, the dressings turn into a gel-like state, capable of absorbing up to 20 times their weight in wound exudate. The fibrous gel thereby creates the desired moist environment for the wound.
  • the dressings can also be removed with a minimal amount of discomfort, minimizes the formation of granulation tissue and does not traumatize epithelial cells during dressing changes.
  • the fibronectin-calcium alginate and other fibronectin solid wound dressings according to the invention can store fibronectin without degradation for long periods of time, at least 12 months at 4°C.
  • the residual moisture in these dressing is low, around 5%.
  • the fibronectin-calcium alginate and other fibronectin- solid wound dressings according to the invention deliver a high concentration of fibronectin into the wound site.
  • the basic mechanisms at play for the fibronectin-calcium alginate dressing is that when this dressing comes into contact with the sodium in the exudate, ion exchange occurs, turning the calcium alginate fibers into a protective non-adherent film gel. In this gel state, fibronectin is free to move from the gel into the wound.
  • Ca ++ forms an insoluble alginate salt and Na + forms a soluble alginate salt (the equivalent ratio of the first to second cations being 50:50, here 0.2M NaCl and 0.2RCaCl2).
  • the maximum homogeneity in the dressing is reached by an appropriate concentration of both gelling and non-gelling cations. Additional Na+ comes from the exudate or, if the wound is too dry or there is no exudate, a small amount of saline _- can be added to the wound immediately prior to placing the dressing.
  • the complex is preferably formed by combining the fibronectin and sodium alginate at a pH which is no higher than the isoelectric point of the protein (pi 6.2) where the fibronectin is positively charged.
  • This pH is achieved by adding glacial acetic acid for a final pH around 5.0. Since acetic acid is highly volatile, a certain amount of acetic acid is removed during the freeze-drying process which is under a vacuum. The final pH of the dressing is around 6.5.
  • the mixed salt alginate dressing exhibits a highly effective combination of properties. For example, there is enough insolubilizing cation in the mixed salt alginate to make the product relatively easy to manipulate. There is also enough solubilizing cation to facilitate the release of fibronectin into the wound.
  • the combination of soluble and insoluble alginate fibers has the further advantage that the dressing is both easily removed after the wound treatment and easily applied initially.
  • Fibronectin-calcium alginate dressing composition Three commercially available preparations of sodium alginate were tested. Protanal LF 120 M sodium alginate (Pronova Biopolymer, Inc., Drammen, Norway) yielded a product more brittle than the preferred embodiment described below. In addition, this sodium alginate yielded a placebo dressing (i.e., control without fibronectin) which was yellowish in appearance compared to the same dressing containing fibronectin. Consequently, this formulation could not be used in human clinical trials. A particularly preferred alginate is Pronova UP LVG sodium alginate (Pronova Biomedical A.S., Oslo, Norway).
  • the fibronectin- calcium alginate wound dressing is prepared as follows: 5 g of sodium alginate (Protanal LF 10/60, Pronova Biopolymer, Drammen, Norway) are dispersed in 95 g of deionized and demineralized water with a paddle type stirrer for about 1 hour. The colloidal dispersion thus produced provides a concentrated sodium alginate base (5 % w/w), which is then autoclaved. The pH of a sterile filtered 1% solution of sodium alginate prepared from this concentrate is adjusted to 4.0 using acetic acid (3.33 ⁇ L of glacial acetic 17.4N in 100 Ml of demineralized water provides a pH of 4.0).
  • Tap water is demineralized using a MiUipore MiUi-Q water system.
  • the terms demineralized and deionized are used interchangeably throughout this application.
  • the pH of 10 mL demineralized water is adjusted to pH 8.0 to 11.0 as described in Example 9.
  • the pH is adjusted to 11.6.
  • 0.025 to 0.1 g, preferably 0.1 g, of lyophilized human plasma fibronectin, prepared according to Example 10 is next dissolved in demineralized water, pH 11.6.
  • the solution is maintained at 37°C until the fibronectin is completely dissolved.
  • the fibronectin solution is then filtered through a 0.22 ⁇ m acetate filter. This solution constitutes the stock fibronectin solution used in this and subsequent examples.
  • 3.4 ml of the resulting 0.25% to 1% sterile solution of fibronectin is then mixed with 1.5 mL of the pH adjusted, dilute sodium alginate solution described above.
  • the sterile fibronectin and sterile sodium alginate solutions are mixed into syringes taking care to avoid the introduction of air bubbles. Contamination is avoided by working in an aseptic environment, such as under a laminar flow hood. Generally, two syringes are used, and multiple exchanges under pressure are applied.
  • An adapter device such as a female luer connection can be used to connect the syringes or other exchange devices. Vigorous agitation is minimized in order to avoid fibronectin precipitation.
  • Gellation of the solution is achieved by the addition of 15 ⁇ L 0.2 M NaCl + 0.2 M CaCl2 and 3.4 ⁇ L of glacial acetic acid.
  • the fibronectin-calcium alginate complex is deposited in a borosilicate glass vial (5 mL for a surface area of 5.3 cm ) and frozen at -20°C for 2 hours and 30 minutes at -80°C.
  • a preferred vial is 22.5 mm in width, 46.5 mm in height with an aluminum seal (part no. 24-0396,
  • solid wound dressings could also be prepared with other insoluble fibers. They could be any insoluble fibers or materials which does not have adverse effect on the wound.
  • suitable plant polysaccharides are carrageenans and cellulose derivatives for instance carboxymethylcellulose or hydroxypropylcellulose are described in the following examples.
  • An embodiment using a synthetic carbomer resin is also illustrated.
  • Tissue matrices and artificial skin systems for example, as described in U.S. Patent 4,963,489, entitled "Three-Dimensional Cell and Tissue Culture system, incorporated by reference, can also be employed in embodiments of the present invention.
  • GPR® CMC BDH Laboratories, Ville St-
  • a solid wound dressing containing (w/w) fibronectin 62%, CMC 38% was prepared as follows. CMC powder was first sterilized by using a dry-heat sterilization process at 121°C for 30 minutes using an American Sterilizer 2020 Vacamtic Eagle series autoclave (Steris Corp., Ohio). 6 grams of CMC were dispersed in 94 mL of demineralized water and mixed with a paddle type stirrer for about 3 hours. This provides a sterile concentrated hydrogel base (6% w/w).
  • lyophilized human plasma fibronectin prepared according to Example 10, was dissolved in deionized water (5 mL) containing 12 ⁇ L of NaOH 3M, for a final pH of 11.6. The solution was maintained at 37°C until the complete solubilization of fibronectin occurred. This stock solution of fibronectin 10 mg/mL was filtered through a 0.22 ⁇ m acetate filter. 3.3 mL of this fibronectin solution was then added to 0.34 g of the concentrated CMC base and mixed with syringes as described in Example 1. The pH is adjusted to 7.0 with the addition of 25 ⁇ L HC1 IN.
  • the homogenous solution of the fibronectin-CMC complex was deposited in a plastic mold and frozen.
  • a Costar 6-well polystyrene cell culture cluster, 9.6 cm 2 rounded surface area (Corning Inc., Corning, NY) was used as the plastic mold.
  • the water is then removed by freeze-drying using a Labconco freeze-dryer (model 77580, Kansas City, MO). By this technique, a fibronectin-CMC wound dressing with a sponge-like structure is produced.
  • Solid hydroxypropylcellulose (HPC) dressing was prepared using the preferred grade of Klucel-HF® HPC (Aqualon, Houston, Texas).
  • a solid wound dressing containing (w/w) fibronectin 45%, HPC 55% was prepared as follows. HPC powder was first sterilized by using a dry- heat sterilization process at 121°C for 30 minutes using an American Sterilizer 2020 Vacamtic Eagle series autoclave (Steris Corp., Ohio). HPC (6 g) was then dispersed in 94 mL of deionized water and mixed with a paddle type stirrer for about 3 hours. This provides a sterile, concentrated hydrogel base (6% w/w).
  • lyophilized human plasma fibronectin prepared according to Example 10, were dissolved in 5 mL of deionized water containing 12 ⁇ L of NaOH 3M, pH 11.6. The solution was maintained at 37°C until complete solubilization of fibronectin occurred. This stock solution of fibronectin, 10 mg/mL, was filtered through a 0.22 ⁇ m acetate filter.
  • Solid carbomer dressing A solid carbomer dressing was prepared using Carbopol® 974P
  • NF carbomer (BF Goodrich, Cleveland, Ohio) as the preferred grade.
  • a solid wound dressing containing (w/w) fibronectin 75%, carbomer 25% was prepared as follows. 2.80 g of carbomer was dispersed in 97.2 mL of demineralized water and mixed with a paddle type stirrer for about 3 hours. This dispersion is then autoclaved to provide a sterile concentrated hydrogel base (2.80% w/w). 50 mg of lyophilized human plasma fibronectin, prepared according to Example 10, were dissolved in 5mL of deionized water containing 12 ⁇ L of NaOH 3M, pH 11.6. The solution was maintained at 37°C until complete solubilization of fibronectin occurred.
  • This stock solution of fibronectin (10 mg/mL) was filtered through a 0.22 ⁇ m acetate filter. 3.3 mL of the fibronectin solution was then added to 0.04g of concentrated carbomer base and the necessary amount of gelifying promoter (25 ⁇ L NaOH 3M) and mixed with syringes as described in Example 1.
  • This fibronectin carbomer hydrogel is deposited in a plastic mold and frozen.
  • a Costar 6-well polystyrene cell culture cluster, 9.6 cm 2 rounded surface area (Corning Inc., Corning, NY) was used as the plastic mold.
  • the water is then removed by freeze-drying using a Labconco freeze-dryer (model 77580, Kansas City, MO). By this technique, a fibronectin- carbomer wound dressing with a sponge- like structure is produced.
  • Solid carrageenan dressing was prepared.
  • the preferred grade is
  • Gelcarin® NF carrageenan (FMC Corporation Pharmaceutical Division, Newark, Delaware).
  • a solid wound dressing containing (w/w) fibronectin 73%, carbomer 27% was prepared as follows. 2.50 g of carrageenan was dispersed in 97.5 mL of deionized water and allowed to be mixed with a paddle type stirrer for about 3 hours. This dispersion is then autoclaved to provide a sterile concentrated hydrogel base (2.50% w/w). 50 mg of lyophilized human plasma fibronectin, prepared according to Example 10, were dissolved in 5 mL of deionized water containing 12 ⁇ L of NaOH 3M, pH 11.6. The solution was maintained at 37°C until complete solubilization of fibronectin occurred.
  • This stock solution of fibronectin (10 mg/mL) was filtered through a 0.22 ⁇ m acetate filter. 3.3 mL of fibronectin solution was then added to 0.50 g of concentrated carrageenan base and mixed with syringes as described in Example 1. The pH is adjusted to 7.0 with the addition of 60 ⁇ L HC1 1 N. At this point, the homogenous solution of the fibronectin-carrageenan complex is deposited in a plastic mold and frozen. A Costar 6-well polystyrene cell culture cluster, 9.6 cm 2 rounded surface area (Corning Inc., Corning, NY) was used as the plastic mold.
  • a fibronectin-calcium alginate dressing prepared as follows: 10.0 gram of sodium alginate (Protanal LF 10/60, Pronova Biopolymer, Drammen, Norway) is dispersed in 90 g of deionized and demineralized water with a paddle type stirrer for about one hour. This dispersion is then autoclaved to provide a sterile concentrated alginate base (10% w/w).
  • a Costar 6-well polystyrene cell culture cluster, 9.6 cm 2 rounded surface area (Corning Inc., Corning, NY) was used as the plastic mold.
  • the water is then removed by freeze-drying using a Labconco freeze-dryer (model 77580, Kansas City, MO).
  • a fibronectin-calcium alginate wound dressing with a sponge-like structure is produced.
  • the surface area of the final disk is close to 8.96 cm 2 surface area because the disk shrinks during freeze-drying.
  • the amount of fibronectin in the 5mL formulation is 33.3 mg for a concentration of 37 ⁇ g/mm 2 of surface area (33,333 ⁇ g/896 mm 2 ).
  • This fibronectin-calcium alginate dressing was compared to the solid wound dressings dressing of Examples 2-5 for 12 hours in deepithelialized skin diffusion cell system.
  • the deepithelialized skin diffusion cell system utilized in the experiments shown in Figure 1 is described in Beaulieu, U. S. Patent No. 5,877, 149, issued March 2,
  • the amount released represents 34.1 ⁇ g of fibronectin per mm deepithelialized skin surface area and is a significant increase (262%) compared with the 13.0 ⁇ g fibronectin released from 1.0% fibronectin carbomer hydrogel after 12 hours, as described in U.S. Patent No.
  • Example 7 The rabbit ear dermal ulcer model
  • the fibronectin- calcium alginate dressing was prepared according to the method described in Example 1. Control treatment (identified in Figures 2-5) were ulcers treated with 40 ⁇ L of saline alone. The wounds were covered with an occlusive polyurethane film (Tegaderm film, 3M, Minneapolis, MN) to prevent wound desiccation. Neck collars were placed on rabbits for the duration of the experiment. Differences in rates of healing between treatment groups were measured at day 7.
  • the ulcers were bisected and fixed in 10% buffered formalin.
  • the specimens were then dehydrated in graded alcohol and xylene, embedded in paraffin, and sectioned, taking care to obtain a cross section as near as possible to the center of the wound.
  • GAP granulation tissue gap
  • MH maximum height
  • the GAP distance is used to calculate the surface area of the wound by the equation (GAP/ 2) ⁇ . On day 0 (day of surgery), the measured
  • New granulation tissue surface area is the area of wound at day 0 minus the area of wound at day 7, i.e., (GAP [day 0]/2) 2 ⁇ - (GAP [day
  • the new granulation volume is new tissue surface area x MH. Area and volume measurements for new granulation tissue were calculated based on the assumptions that the wounds healed concentrically and did not contract. Statistical analysis was carried out using a Student's paired t test for each formulations studied using
  • fibronectin in a 1.0% fibronectin-carbomer hydrogel formulation on the rabbit dermal ulcer model was evaluated in its capacity to stimulate the formation of new granulation tissue.
  • the fibronectin was applied as a 0.281% carbomer hydrogel, applying a volume of 40 ⁇ L of hydrogel containing 400 ⁇ g of fibronectin.
  • the 1.0% fibronectin-carbomer hydrogel prepared according to Example 9, pH 11.6. This delivered approximately 13 ⁇ g of fibronectin per mm 2 rabbit ulcer surface area as described in U.S. Patent No. 5,821,220.
  • the fibronectin-carbomer hydrogel was applied to the test ulcer once a day for a period of 7 days, starting at the time of surgery.
  • the volume of topical formulations applied to the control wounds was also 40 ⁇ L.
  • Antiseptic tulle gras dressing (Bactigras®, Smith & Nephew, Lachine, Canada) and a non-adherent absorbent dressing (Melolite®, Smith & Nephew, Lachine, Canada) were used to prevent wound desiccation. Before each daily application, the ulcers were washed with sterile saline solution, gently cleaned with a moistened cotton- swab.
  • fibronectin-calcium alginate disks for this experiment are prepared as in Example 1.
  • the disks were stacked and if necessary cut to provide the following dosages of fibronectin, 10.3 ⁇ g/mm 2 , 20.6 ⁇ g/mm 2 , 41.25 ⁇ g/mm 2 , 82.5 ⁇ g/mm 2 , 123.75 ⁇ g/mm 2 , 165 ⁇ g/mm 2 .
  • the results of varying dosages on maximum height (MH) and new granulation volume (NGV) are shown respectively, in Tables 1 and 2 below. Clear benefit from the presence of fibronectin-calcium alginate disks was demonstrated and the effect appears to be dose related, particularly in the range of 10 to 120 ⁇ g/mm 2 .
  • a preferred delivery system of the invention consists of human plasma fibronectin lyophilized in the presence of calcium-alginate to form solid disks, which are to be applied topically to the wound surface to be treated.
  • the use of calcium-alginate disks helps insure the delivery of known, consistent amounts of fibronectin to a wound surface.
  • human fibronectin is purchased as a cryoprecipitate from a licensed manufacturer (Medlmmune, Maryland through DCI Management, New York, NY). The cryoprecipitate extract is first dissolved and clarified.
  • the cryoprecipitate extract is then treated to inactivate lipid enveloped viruses by the solvent/ detergent procedure using 0.3% tri (n-butyl) phosphate (TNBP) and 1% Triton X- 100 for four hours at room temperature.
  • the process reagents are removed and the fibronectin is purified on a gelatin- Sepharose affinity chromatography. Bound fibronectin is eluted from the column with 1M potassium bromide at . pH 5.0. Following the removal of salts, the fibronectin is otoriligod by 100 KD membrane ultrafiltration. sterilized using a 0.22 ⁇ m acetate filter and lyophilized. It is then combined with sterile calcium-alginate as described in Example 1.
  • Sterile glass vials are filled aseptically with 5 mL of the fibronectin/ calcium alginate mixture under Food and Drug Administration, class 100 good manufacturing procedures. Stoppers should be inserted partway into the vials and the preparation is dried on a FTS Duralyophilizer lyophilizer.
  • the prep ⁇ ired disks 4.2 cm 2 in diameter, are removed from the vial by forceps, placed on the wound to be treated and wetted with sterile saline (0.9% NaCl).
  • Each dressing holds 80 ⁇ g of fibronectin per mm 2 of surface area. More than one dressing may be used depending on the size of the skin ulcer or other lesion to be treated and must be trimmed to fit the shape of the wound.
  • the disks may be stacked to deliver larger doses of fibronectin, such as 160 ⁇ g per mm 2 , 240 ⁇ g per mm 2 , and so forth.
  • the dressings according to this and previous examples can be prepared using fibronectin from a non- human source.
  • Representative animals include, but are not limited, to horses, dogs and cats.
  • no other ointments, creams or dressings are applied to the wound, ulcer or other lesion while the fibronectin- solid wound dressing of this example is used.
  • the dressing is preferably applied with high compression therapy using a long stretch four-layer bandage.
  • the foot of the patient's bed that is used for sleeping should be raised to form an angle of about 20 degrees.
  • a two-inch block can be placed under the foot of a human patient's bed or two pillows can be placed between the base and the mattress of the bed. If the patient remains seated or lying down for more than 30 minutes after application, he/she should raise his/her legs. Similarly, if the patient remains in a fixed standing position after application, he/she must walk every 30 minutes. Twice a week, the dressing according to the invention is removed and the wound bed is inspected for evidence of infection. If there are signs of infection, they should be evaluated and treated as necessary by the appropriate health care practitioner.
  • the wound bed is assessed as follows. If at least 50% of the wound bed is pale pink to beefy red (as opposed to gray, yellow, or black indicating necrotic material), then the replacement dressing and compression are applied. If less than 50% of the ulcer bed is pink or red, the wound bed should be debrided, i.e. cleaned of any necrotic material. Debridement should be done with sharp surgical instruments and can be done using local anesthesia.
  • fibronectin carbomer hydrogel To prepare 10 g of fibronectin carbomer hydrogel, the following ingredients must be added in sequence. First, the pH of 8.8 mL demineralized water, pH 5.0, is adjusted to pH 8.0 to 11.0 by adding 2.95 ⁇ g to 2.95 mg NaOH 3M. Demineralized water from different sources may have different starting pH values and the exact amount of NaOH 3M can be adjusted as need to the desired value.
  • lyophilized fibronectin 0.05 to 0.1 grams are dissolved in the demineralized water, pH 8.0 to 11.0.
  • 1 mL of water containing 0.028 g of carbomer and 0.09399705 g to 0.09105 g of NaOH 3M are added to the mixture.
  • Examples of the composition for several fibronectin carbomer hydrogels are shown in Table 2. "FN" stands for lyophilized fibronectin.
  • the following ingredients must be added in this sequence.
  • the pH of demineralized water (8.856 or 8.806 grams) is adjusted to 11.6 with 0.0235 grams of NaOH 3M.
  • 8.856 grams of water is utilized when 0.05 grams of fibronectin will be added;
  • 8.806 grams of water is utilized when 0.1 grams of fibronectin will be added.
  • 0.05 or 0.1 grams of lyophilized fibronectin is next dissolved in the demineralized basic water.
  • 0.028 grams of carbomer and 0.0705 grams of NaOH 3M are added to the mixture.
  • the 0.028 grams of carbomer comes from 1.0 gram of a 2.8% carbomer stock solution.
  • the concentrated carbomer stock solution may be at 3.75% or 2.80%.
  • the preparation of fibronectin carbomer hydrogels using different concentrated stock solutions is illustrated in Table 2.
  • a preferred grade of carbomer is Carbopol® 974P NF carbomer (BF Goodrich, Cleveland, Ohio).
  • the fibronectin concentration is measured by the well-known micro-Bradford method.
  • the Bradford protein assay is based upon the Bradford dye-binding procedure (Bradford, M. Anal. Biochem. 72, 248, 1976).
  • the protein assay is based on the color change of Coomassie® Brillant Blue G-250 dye, in response to various concentrations of protein.
  • Example 10 Solvent/ detergent-treated human homologous plasma fibronectin The lyophilized fibronectin used in Examples 1-7 and 9 was prepared as described in this example.
  • HBV hepatitis B and C virus
  • HCV human immunodeficiency virus
  • HMV human T-cell lymphotrophic virus
  • CMV cytomegalovirus
  • a viral inactivation solvent/ detergent method using tri(n-butyl)phosphate (TNBP) and Triton X- 100 is performed.
  • Treatment of plasma products with organic solvent, tri(n- butyl)phosphate (TNBP) and Triton X- 100 detergent was shown to inactivate very large quantities of HBV, HCV and HIV (Horowitz et al., 1992, Blood 79 (3):826-31 without affecting labile proteins such as fibronectin.
  • frozen plasma from 5 donors is thawed and treated while stirring for 6 hours with 1% (vol/vol) TNBP, 1% (vol/vol) Triton X- 100 and 1 mM phenylmethylsulfonyl fluoride at 24°C.
  • soybean oil (20% vol/vol) is added, mixed gently for 30 minutes at ambient temperature, and then removed by using a decantation funnel at 4°C.
  • fibronectin is purified from plasma, for example by the gelatin- Sepharose affinity chromatography procedure described below, the final solution is verified for contamination by TNBP and Triton X- 100.
  • TNBP is quantified in a sample of purified fibronectin after hexane extraction by gas chromatography using a 0.25-in by 2 mm ID by 4-ft glass column packed with 10% SP- 1000 on a 80/ 100 mesh Supelcoport (Supelco, Bellafonte, PA).
  • Triton X-100 was assayed by injecting a sample of purified fibronectin to high liquid chromatography (HPLC) on a gel filtration column G2000 SW 7.5 mm ID by 60 cm (Tosohass) coupled with a UV detector set at 230 nm.
  • Fibronectin preparations were found to contain less that 1 ppm of either TNBP or Triton X-100. Fibronectin was isolated from solvent/ detergent-treated human plasma using a gelatin- Sepharose affinity chromatography procedure
  • gelatin is covalently coupled to Sepharose CL-
  • the binding capacity for human plasma fibronectin provided by this system is > 1 mg/mL of gel.
  • the purificaton is performed in a batch procedure with a glass funnel filter holder (Costar Nucleopore, Pleasanton, CA) with a capacity of 375 mL
  • the plasma sample is passed twice on a gelatin-
  • Sepharose gel The matrix is washed with several volumes of 0.15 M Tris-HCl buffer pH 7.5, several volumes of 0.15 M Tris-HCl buffer pH 7.5 + 1 M NaCl and again with 0.15 M Tri-/HCl buffer pH 7.5. Elution is carried out with 1 M KBr in 0.1 M acetate buffer pH 5.0. The resulting solution of fibronectin is then exhaustively dialyzed against deionized and demineralized water, ultrafiltered under nitrogen, lyophilized and frozen at -80°C until used.
  • the protein concentration is determined using the Bio-Rad protein assay (Bio-Rad Laboratories, Richmond, CA). The following diagram summarizes the purification steps.
  • Fibronectin from non-human animals can be purified using similar methods. The lots of plasma would be screened for atypical antibodies as appropriate for the source organism and known to those skilled in the art.
  • the viral inactivation solvent/ detergent method (25°C for 6 h) as described in the previous example has been recognized to be highly effective in the destruction of enveloped- viruses.
  • Radosevich (Seminars in Thrombosis and Hemostasis. 24 (2) 157- 161,1998)
  • pasteurization has broader virucidal action owing to its additional ability to inactivate non-enveloped viruses.
  • Non-enveloped viruses are usually more resistant to physicochemical treatments than enveloped viruses.
  • improvements in viral safety for plasma products may be obtained by combining different viral reduction procedures (e.g. solvent-detergent + dry heat treatments).
  • An additional dry heat treatment on lyophilized solvent- detergent treated-fibronectin at 68°C for 96 hours can be performed before incorporating the fibronectin in the wound formulations of the invention described in the previous examples.
  • 50 mg of lyophilized fibronectin prepared according to Example 10 was placed in a 50 mL polypropylene conical tube (Becton Dickinson Labware, Franklin Lakes, NJ) using sterile techniques and sealed. The tube is then submerged in a well-controlled water bath (Exacal Ex- 110 water bath Neslab Instruments, Newington, NJ) at 68°C for 96 hours.
  • Human or veterinary fibronectin produced by recombinant means may be utilized in the solid wound dressings of the invention in place of the plasma fibronectin purified and sterilized according to the methods described in the previous examples.
  • Active fragments of fibronectin or modified fibronectin fragments may be utilized in alternative embodiments of the invention, using methods well known in the art. Such methods include recombinant DNA methods and chemical synthesis methods for production of proteins.
  • recombinant fibronectin polypeptide fragments can be made in bacteria or chemically synthesized.
  • Fibronectin, fibronectin polypeptide fragments or any polypeptide compound used in the invention can be isolated from animal tissue or plasma or produced and isolated from cell culture.
  • fibronectin may be produced and isolated from genetically altered animals, such as transgenic animals, to generate more endogenous or exogenous forms of fibronectin. Sequences of fibronectin are known to one skilled in the art, for example, as in Kornblihtt et al., EMBO J. 4: 1755- 1759 (1985), incorporated herein by reference, or, are available from Genbank, NCBI, NIH, and easily searchable, on the internet at http:/ /www.ncbi.nlm.nih.gov. F ⁇ ublicly available databases are incorporated herein by reference in their entirety.
  • fibronectin fragments are disclosed in: U.S. Patent No. 5,453,489, entitled “Polypeptide fragments of fibronectin which can modulate extracellular matrix assembly”; U.S. Patent No. 5,958,874, entitled “Recombinant fibronectin-based extracellular matrix for wound healing”; and U.S. Patent No.
  • Wound healing promoters other than fibronectin can include other wound healing promoter having a composition similar to fibronectin, such as proteins of similar size (extracellular matrix proteins, e.g. throbospondin, laminin, vitronectin, fibrinogen) or smaller size (such as peptides including growth factors, e.g., platelet-derived growth factor).
  • proteins of similar size extracellular matrix proteins, e.g. throbospondin, laminin, vitronectin, fibrinogen
  • smaller size such as peptides including growth factors, e.g., platelet-derived growth factor.
  • the appropriate species -specific wound healing promoters are used, i.e., human fibronectin and/ or other wound healing promoters for human applications.

Abstract

L'invention concerne une solution concentrée d'un promoteur de guérison de plaies, notamment la fibronectine, utilisée pour former des pansements solides. Ces pansements contenant de la fibronectine sont faciles à appliquer, faciles à retirer et administrent la fibronectine en quantités physiologiquement actives.
PCT/CA2000/000953 1995-06-07 2000-08-21 Formulations solides contenant de la fibronectine, destinees a la guerison de plaies WO2001013967A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU66763/00A AU781865B2 (en) 1999-08-20 2000-08-21 Solid wound healing formulations containing fibronectin
EP00954211A EP1210130A1 (fr) 1999-08-20 2000-08-21 Formulations solides contenant de la fibronectine, destinees a la guerison de plaies
JP2001518100A JP2003507440A (ja) 1999-08-20 2000-08-21 フィブロネクチンを含む固形創傷治癒用組成物
CA002380730A CA2380730A1 (fr) 1999-08-20 2000-08-21 Formulations solides contenant de la fibronectine, destinees a la guerison de plaies
GB0203693A GB2368523B (en) 1999-08-20 2000-08-21 Solid wound healing formulations containing fibronectin
MXPA02001576A MXPA02001576A (es) 1999-08-20 2000-08-21 Formulaciones solidas con un contenido de fibronectina para la cicatrizacion de heridas.
US10/049,992 US7112320B1 (en) 1995-06-07 2000-08-21 Solid wound healing formulations containing fibronectin

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14995899P 1999-08-20 1999-08-20
US60/149,958 1999-08-20
US18241200P 2000-02-14 2000-02-14
US60/182,412 2000-02-14

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/145,678 A-371-Of-International US20030105007A1 (en) 1995-06-07 2002-05-15 PDGF-betabeta and fibronectin combined in a solid wound dressing for the treatment of wounds

Publications (1)

Publication Number Publication Date
WO2001013967A1 true WO2001013967A1 (fr) 2001-03-01

Family

ID=26847182

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/000953 WO2001013967A1 (fr) 1995-06-07 2000-08-21 Formulations solides contenant de la fibronectine, destinees a la guerison de plaies

Country Status (7)

Country Link
EP (1) EP1210130A1 (fr)
JP (1) JP2003507440A (fr)
AU (1) AU781865B2 (fr)
CA (1) CA2380730A1 (fr)
GB (1) GB2368523B (fr)
MX (1) MXPA02001576A (fr)
WO (1) WO2001013967A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2253665A1 (fr) * 2009-04-22 2010-11-24 Dr. Suwelack Skin & Health Care AG Composition lyophilisée
EP2489338A1 (fr) * 2006-08-28 2012-08-22 Rexaderm, INC. Pansement de plaie sec et système de délivrance de médicament
CN113577378A (zh) * 2021-08-28 2021-11-02 上海纤瑞生物技术有限公司 一种纤连蛋白液体伤口喷剂敷料及其制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101862B2 (en) * 2001-12-31 2006-09-05 Area Laboratories, Llc Hemostatic compositions and methods for controlling bleeding
JP2020070270A (ja) * 2018-11-01 2020-05-07 御木本製薬株式会社 フィブロネクチン遺伝子発現促進剤

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784989A (en) * 1982-09-14 1988-11-15 Hoeoek Magnus Means for removing microorganisms from tissue
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
EP0572272A1 (fr) * 1992-05-29 1993-12-01 JOHNSON & JOHNSON MEDICAL, INC. Agent de cicatrisation osseuse résorbable
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
WO1998012228A1 (fr) * 1996-09-19 1998-03-26 The Regents Of The University Of Michigan Polymeres contenant des polyosides tels que des alginates ou des alginates modifies
US5877149A (en) * 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
WO1999027167A1 (fr) * 1997-11-26 1999-06-03 Intercytex Limited Procede pour la production de fibres proteiniques et produits a base de ces fibres

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124155A (en) * 1988-06-21 1992-06-23 Chiron Ophthalmics, Inc. Fibronectin wound-healing dressings

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4784989A (en) * 1982-09-14 1988-11-15 Hoeoek Magnus Means for removing microorganisms from tissue
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
US5610148A (en) * 1991-01-18 1997-03-11 University College London Macroscopically oriented cell adhesion protein for wound treatment
US5629287A (en) * 1991-01-18 1997-05-13 University College London Depot formulations
EP0572272A1 (fr) * 1992-05-29 1993-12-01 JOHNSON & JOHNSON MEDICAL, INC. Agent de cicatrisation osseuse résorbable
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
US5877149A (en) * 1995-06-07 1999-03-02 Beaulieu; Andre Deepithelialized skin diffusion cell system
WO1998012228A1 (fr) * 1996-09-19 1998-03-26 The Regents Of The University Of Michigan Polymeres contenant des polyosides tels que des alginates ou des alginates modifies
WO1999027167A1 (fr) * 1997-11-26 1999-06-03 Intercytex Limited Procede pour la production de fibres proteiniques et produits a base de ces fibres

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2489338A1 (fr) * 2006-08-28 2012-08-22 Rexaderm, INC. Pansement de plaie sec et système de délivrance de médicament
US8377468B2 (en) 2006-08-28 2013-02-19 Rexaderm, Inc. Dry wound dressing and drug delivery system
EP2253665A1 (fr) * 2009-04-22 2010-11-24 Dr. Suwelack Skin & Health Care AG Composition lyophilisée
US9822243B2 (en) 2009-04-22 2017-11-21 Dr. Suwelack Skin & Health Care Ag Freeze-dried composition
CN113577378A (zh) * 2021-08-28 2021-11-02 上海纤瑞生物技术有限公司 一种纤连蛋白液体伤口喷剂敷料及其制备方法和应用

Also Published As

Publication number Publication date
GB0203693D0 (en) 2002-04-03
JP2003507440A (ja) 2003-02-25
CA2380730A1 (fr) 2001-03-01
EP1210130A1 (fr) 2002-06-05
GB2368523B (en) 2004-05-12
GB2368523A (en) 2002-05-08
MXPA02001576A (es) 2004-08-12
AU781865B2 (en) 2005-06-16
AU6676300A (en) 2001-03-19

Similar Documents

Publication Publication Date Title
Shah et al. Biopolymer-based biomaterials for accelerated diabetic wound healing: A critical review
Rajendran et al. A review on nanoparticle based treatment for wound healing
JP7013336B2 (ja) インサイチュー架橋性ポリマー組成物およびその方法
Moraes et al. Bacterial cellulose/collagen hydrogel for wound healing
Laurano et al. Wound dressing products: A translational investigation from the bench to the market
Aramwit Introduction to biomaterials for wound healing
US6559119B1 (en) Method of preparing a tissue sealant-treated biomedical material
US6132759A (en) Medicaments containing gelatin cross-linked with oxidized polysaccharides
US6117425A (en) Supplemented and unsupplemented tissue sealants, method of their production and use
US7229959B1 (en) Supplemented fibrin matrix delivery systems
USRE39298E1 (en) Supplemented and unsupplemented tissue sealants, methods of their production and use
JP5553769B2 (ja) 皮膚創傷治癒のためのエリスロポエチンの局所適用および製剤
RU2422133C1 (ru) Гидрофильный гель, способ его получения (варианты), раневое покрытие и перевязочное средство на его основе
CA2290806A1 (fr) Nouveaux medicaments bases sur des polymeres composes de gelatine a modification methacrylamide
JPH04502569A (ja) 創傷治療用ゲル配合物
WO1996017633A9 (fr) Colles tissulaires adjuventees et non adjuventees, procedes de production et d'utilisation
EP0796115A1 (fr) Colles tissulaires adjuventees et non adjuventees, procedes de production et d'utilisation
Sheokand et al. Natural polymers used in the dressing materials for wound healing: Past, present and future
Ghadi et al. Microparticulate polymers and hydrogels for wound healing
CN111150838A (zh) 一种促创面愈合的胶原蛋白水凝胶及其制备方法
US7112320B1 (en) Solid wound healing formulations containing fibronectin
AU781865B2 (en) Solid wound healing formulations containing fibronectin
Choi et al. Amniotic membrane extract-loaded double-layered wound dressing: evaluation of gel properties and wound healing
AU747209B2 (en) Wound healing formulations containing human plasma fibronectin
US20030105007A1 (en) PDGF-betabeta and fibronectin combined in a solid wound dressing for the treatment of wounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2380730

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 66763/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/001576

Country of ref document: MX

ENP Entry into the national phase

Ref country code: GB

Ref document number: 200203693

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000954211

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000954211

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10049992

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 66763/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 2000954211

Country of ref document: EP